U.S. market Closed. Opens in 17 hours 9 minutes

HCWB | HCW Biologics Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.6000 - 0.6350
52 Week Range 0.4000 - 2.1810
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 11,124
Average Volume 23,182
Shares Outstanding 37,823,400
Market Cap 22,694,040
Sector Healthcare
Industry Biotechnology
IPO Date 2021-07-20
Valuation
Profitability
Growth
Health
P/E Ratio -0.57
Forward P/E Ratio N/A
EPS -1.05
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 45
Country USA
Website HCWB
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
*Chart delayed
Analyzing fundamentals for HCWB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see HCWB Fundamentals page.

Watching at HCWB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HCWB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙